Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Home Print this page Email this page
Users Online:212
Year : 2013  |  Volume : 1  |  Issue : 3  |  Page : 67-72

Managing heart failure in 2013: Changing paradigms

Department of Cardiology, King George's Medical College, Lucknow, Uttar Pradesh, India

Correspondence Address:
Akshyaya Kumar Pradhan
Department of Cardiology, King George's Medical College, Lucknow - 226 003, Uttar Pradesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2321-449x.122779

Rights and Permissions

Heart failure (HF) imposes huge morbidity and mortality on society. In recent times, HF with preserved ejection fraction (EF) has emerged as the predominant form of HF syndromes. Natriuretic peptides (B-type natriuretic peptide [BNP] and N-terminal [NT] pro BNP) have now emerged as preferred biomarkers for diagnosis and guiding further therapy in HF. Ivabradine and Eplerenone are now approved for HF patients who are symptomatic despite optimal therapy. Tolvaptan has been shown to improve hyopnatremia as well as dyspnea in patients of HF. Coronary bypass grafting has demonstrated a decrease in cardiovascular death and HF hospitalization in patients with of HF with angina. Cardiac resynchronization therapy has now consistently shown to decrease mortality in Mild HF.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded1358    
    Comments [Add]    

Recommend this journal